Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 13/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TOP2A | P11388 | 3/20 | 0.96 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Furamidine SCHEMBL31175984 | 0.98 | TOP2A (1.00) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| Furamidine SCHEMBL7734063 | 0.98 | TOP2A (1.00) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL4357250 | 0.98 | NQO2 (0.96) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| Hydrochloric Acid SCHEMBL3506114 | 0.96 | TOP2A (0.96) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL13573592 | 0.90 | NQO2 (0.81) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL23566020 | 0.89 | NQO2 (0.79) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL3505723 | 0.89 | NQO2 (0.79) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL397579 | 0.86 | NQO2 (0.75) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL14390576 | 0.86 | NQO2 (0.73) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL14599566 | 0.86 | NQO2 (1.00) | NQO2PRMT1ALDH1A1TOP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584131-B2 | Methods of gene therapy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| WO-2025059144-A1 | DYNAMIC NANOMECHANICAL AMPLIFICATION ANTENNA AND USES | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| CN-118001405-A | Use of Prmt1 inhibitors in the treatment of acute liver injury | 中国药科大学 | 2024-05-10 | — | — | CN | claimed |
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | UNIVERSITY OF VIRGINIA | 2022-06-02 | — | — | US | claimed |
| US-20220144902-A1 | METHOD FOR INDUCING MUSCULAR CELLS USING CELLS IN SPOT URINE | NIPPON SHINYAKU CO., LTD. (JP) | 2022-05-12 | — | — | US | claimed |
| WO-2009124941-A2 | TRYPANOCIDAL COMPOUNDS TARGETED TO TRYPANOSOMES INTERIOR | AARHUS UNIVERSITET (DK) | 2009-10-15 | — | — | WO | claimed |
| US-20070276020-A1 | Dicationic Compounds For Activity Against Trichomonas Vaginalis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | claimed |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-0792271-B1 | FURAN DERIVATIVES FOR INHIBITING PNEUMOCYSTIS CARINII PNEUMONIA, GIARDIA LAMBLIA AND CRYPTOSPORIDIUM PARVUM | UNIV GEORGIA STATE RES FOUND (US) | 2002-02-27 | — | — | EP | claimed |
| EP-0792271-A1 | FURAN DERIVATIVES FOR INHIBITING PNEUMOCYSTIS CARINII PNEUMONIA, GIARDIA LAMBLIA AND CRYPTOSPORIDIUM PARVUM | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1997-09-03 | — | — | EP | claimed |
| US-5602172-A | USING A 2,5-DIPHENYLFURAN COMPOUND | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-11 | — | — | US | claimed |
| WO-1996015126-A1 | FURAN DERIVATIVES FOR INHIBITING PNEUMOCYSTIS CARINII PNEUMONIA, GIARDIA LAMBLIA AND CRYPTOSPORIDIUM PARVUM | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1996-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | DDIT3, PRMT3, PRMT1 | NQO2 1858/4885PRMT1 3/4885ALDH1A1 2651/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | NQO2 132/4885PRMT1 2584/4885ALDH1A1 662/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | NQO2 129/4885PRMT1 1095/4885ALDH1A1 1543/4885 |
| US-20070276020-A1 | Dicationic Compounds For Activity Against Trichomonas Vaginalis | CASP12, DLD, HDAC5 | NQO2 1046/4885PRMT1 1577/4885ALDH1A1 3778/4885 |
| US-12584131-B2 | Methods of gene therapy | CYP7A1, POR, CYP4A22 | NQO2 983/4885PRMT1 4534/4885ALDH1A1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.